Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Febuxostat Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 40mg
  • 1.3.3 80mg
  • 1.3.4 20mg
  • 1.3.5 120mg
• 1.4 Market Segment by Application
  • 1.4.1 Global Febuxostat Market Share by Application (2019-2025)
  • 1.4.2 Acute Gout
  • 1.4.3 Chronic Gout
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Febuxostat Market Size
  • 2.1.1 Global Febuxostat Revenue 2014-2025
  • 2.1.2 Global Febuxostat Sales 2014-2025
• 2.2 Febuxostat Growth Rate by Regions
  • 2.2.1 Global Febuxostat Sales by Regions 2014-2019
  • 2.2.2 Global Febuxostat Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Febuxostat Sales by Manufacturers
  • 3.1.1 Febuxostat Sales by Manufacturers 2014-2019
  • 3.1.2 Febuxostat Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Febuxostat Revenue by Manufacturers (2014-2019)
  • 3.2.2 Febuxostat Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Febuxostat Market Concentration Ratio (CR5 and HHI)
• 3.3 Febuxostat Price by Manufacturers
• 3.4 Key Manufacturers Febuxostat Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Febuxostat Market
• 3.6 Key Manufacturers Febuxostat Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 40mg Sales and Revenue (2014-2019)
  • 4.1.2 80mg Sales and Revenue (2014-2019)
  • 4.1.3 20mg Sales and Revenue (2014-2019)
  • 4.1.4 120mg Sales and Revenue (2014-2019)
• 4.2 Global Febuxostat Sales Market Share by Type
• 4.3 Global Febuxostat Revenue Market Share by Type
• 4.4 Febuxostat Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Febuxostat Sales by Application

6 United States

• 6.1 United States Febuxostat Breakdown Data by Company
• 6.2 United States Febuxostat Breakdown Data by Type
• 6.3 United States Febuxostat Breakdown Data by Application

7 European Union

• 7.1 European Union Febuxostat Breakdown Data by Company
• 7.2 European Union Febuxostat Breakdown Data by Type
• 7.3 European Union Febuxostat Breakdown Data by Application

8 China

• 8.1 China Febuxostat Breakdown Data by Company
• 8.2 China Febuxostat Breakdown Data by Type
• 8.3 China Febuxostat Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Febuxostat Breakdown Data by Company
• 9.2 Rest of World Febuxostat Breakdown Data by Type
• 9.3 Rest of World Febuxostat Breakdown Data by Application
• 9.4 Rest of World Febuxostat Breakdown Data by Countries
  • 9.4.1 Rest of World Febuxostat Sales by Countries
  • 9.4.2 Rest of World Febuxostat Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Takeda Pharmaceuticals
  • 10.1.1 Takeda Pharmaceuticals Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Febuxostat
  • 10.1.4 Febuxostat Product Introduction
  • 10.1.5 Takeda Pharmaceuticals Recent Development
• 10.2 MACLEODS
  • 10.2.1 MACLEODS Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Febuxostat
  • 10.2.4 Febuxostat Product Introduction
  • 10.2.5 MACLEODS Recent Development
• 10.3 Prinston Pharmaceutical
  • 10.3.1 Prinston Pharmaceutical Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Febuxostat
  • 10.3.4 Febuxostat Product Introduction
  • 10.3.5 Prinston Pharmaceutical Recent Development
• 10.4 Alembic Pharmaceuticals
  • 10.4.1 Alembic Pharmaceuticals Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Febuxostat
  • 10.4.4 Febuxostat Product Introduction
  • 10.4.5 Alembic Pharmaceuticals Recent Development
• 10.5 Hikma Pharmaceuticals
  • 10.5.1 Hikma Pharmaceuticals Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Febuxostat
  • 10.5.4 Febuxostat Product Introduction
  • 10.5.5 Hikma Pharmaceuticals Recent Development
• 10.6 Lupin Limited
  • 10.6.1 Lupin Limited Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Febuxostat
  • 10.6.4 Febuxostat Product Introduction
  • 10.6.5 Lupin Limited Recent Development
• 10.7 Mylan
  • 10.7.1 Mylan Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Febuxostat
  • 10.7.4 Febuxostat Product Introduction
  • 10.7.5 Mylan Recent Development
• 10.8 Teijin Pharma
  • 10.8.1 Teijin Pharma Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Febuxostat
  • 10.8.4 Febuxostat Product Introduction
  • 10.8.5 Teijin Pharma Recent Development
• 10.9 Hengrui Pharma
  • 10.9.1 Hengrui Pharma Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Febuxostat
  • 10.9.4 Febuxostat Product Introduction
  • 10.9.5 Hengrui Pharma Recent Development
• 10.10 Sun Pharma
  • 10.10.1 Sun Pharma Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Febuxostat
  • 10.10.4 Febuxostat Product Introduction
  • 10.10.5 Sun Pharma Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Febuxostat Sales Channels
  • 11.2.2 Febuxostat Distributors
• 11.3 Febuxostat Customers

12 Market Forecast

• 12.1 Global Febuxostat Sales and Revenue Forecast 2019-2025
• 12.2 Global Febuxostat Sales Forecast by Type
• 12.3 Global Febuxostat Sales Forecast by Application
• 12.4 Febuxostat Forecast by Regions
  • 12.4.1 Global Febuxostat Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Febuxostat Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Febuxostat can effectively reduce the risk of gout and hyperuricemia by stably controlling the patient's uric acid value.
Febuxostat is a uric acid production inhibitor. It is an activity that can hinder the production of blood uric acid in the body - xanthine oxidase. Then the body normally metabolizes excess uric acid from the body. Therefore, it will not increase the burden of liver and kidney, and patients with low liver and kidney function can also take this drug conveniently.
In 2019, the market size of Febuxostat is 850 million US$ and it will reach 2020 million US$ in 2025, growing at a CAGR of 11.4% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Febuxostat.

This report studies the global market size of Febuxostat, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Febuxostat sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Takeda Pharmaceuticals
MACLEODS
Prinston Pharmaceutical
Alembic Pharmaceuticals
Hikma Pharmaceuticals
Lupin Limited
Mylan
Teijin Pharma
Hengrui Pharma
Sun Pharma

Market Segment by Product Type
40mg
80mg
20mg
120mg

Market Segment by Application
Acute Gout
Chronic Gout

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Febuxostat status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Febuxostat manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Febuxostat are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025